依普利酮要注意什么事项呢？

(Eplerenone) is a new type of selective aldosterone receptor blocker that can effectively control hypertension, reduce damage to target organs such as the heart, brain and kidneys, and improve microalbuminuria in patients with type 2 diabetes. Eplerenone is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the U.S. Food and Drug Administration in 2002. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. It is a good alternative to spironolactone.

Eplerenone can be used alone or in combination with other antihypertensive drugs. The recommended initial dose of eplerenone when used alone is 50 mg once per day. Obvious pressure-reducing effect will appear within four weeks of taking the medicine. If the pressure effect is not obvious, it can be increased to 50mg/time, 2 times/day. Higher dosages are not recommended, otherwise there is an increased risk of adverse reactions such as hyperkalemia.

Precautions when using eplerenone:

(1) Eplerenone cannot be combined with potassium supplements, potassium-containing salts or contraindicated drugs (potassium-sparing diuretics, strong inhibitors of CYP450 liver enzymes).

(2) Non-steroidal anti-inflammatory drugs and lithium can affect the blood concentration of eplerenone and affect its efficacy.

(3) Patients with high serum potassium, type 2 diabetes patients with microalbuminuria, patients with high serum creatinine levels, and patients with muscle intoxication clearance <50 mL/min should not take Eplerenone.